Painchek Ltd · ASX:PCK
Painchek — Investor Presentation (October 2018)
31 slides from Painchek's investor presentation, Oct 16, 2018
Slide 1: Company Presentation October 2018
For personal use only Company Presentation October 2018 PainChek Ltd ASX:PCK 1
Slide 2: Our 'Why'
OUR ‘WHY’ For personal use only Our purpose is to give a voice to people who cannot verbalise their pain 2
Slide 3: PainChek Highlights
PainChek® Highlights Large initial global market For personal use only opportunities 47M people living with dementia Proven business model worldwide - CAGR 3% Accelerating sales in Residential Aged 400M children aged between 0-3 years Care (RAC) including Allity, Top 5 RAC old Partnering with 3rd Pa
Slide 4: Our Initial Target Markets
Our Initial Target Markets For personal use only Carers of non-communicative people Nannies, with pain: BabysittersD ay Care Staff Doctors Children, Parents ▪ Dementia sufferers & Grandparents ▪ Pre-verbal children Nurses Day Care Centres Carers of people who cannot self- GP, Outpatient, report thei
Slide 5: Initial Market Opportunity – Carers of people living with Dementia
PainChek® Initial Market Opportunity – Carers of people living with Dementia 6,000,000 people For personal use only living with 7,500,000 dementia1 people living with dementia1 US 18,000,000 carers of people with dementia5 400,000 people 6,500,000 health care living with professionals who could use
Slide 6: New Market Opportunity: pre-verbal children's App
New Market Opportunity: pre-verbal children’s App For personal use only • Children’s App developed with facial recognition capability • Clinical trial sites identified – in negotiation with major Australian children’s hospital • Trials scheduled to commence Q4 2108 • Product launch scheduled for 201
Slide 7: The Team
THE TEAM For personal use only Prof. Jeff Hughes Mustafa Atee Philip Daffas Chief Scientific Officer PhD, MPS Research Scientist MPS, PhD (candidate) CEO & Managing Director, MBA, BSc Jeff is a professor in the School of Pharmacy, Mustafa is a clinical, community and academic Philip is a highly acco
Slide 8: The Challenge of Managing Pain for People with Dementia
THE CHALLENGE OF MANAGING PAIN FOR PEOPLE WITH DEMENTIA For personal use only Pain is common • Up to 80% of people in aged care experience chronic pain1 • More than 50% of people in Australian aged care have dementia2 • 47 Million globally living with Dementia3 growing at 3% p.a. But pain often goes
Slide 9: Clinical Benefits of Accurately Identifying Pain
CLINICAL BENEFITS OF ACCURATELY IDENTIFYING PAIN For personal use only Accurately identifying pain can • Improve quality of life • Reduce rates and severity of behaviours • Reduce rates of incorrectly prescribed antipsychotics • Improve staff retention 9
Slide 10: Evolution of Pain Assessments in Dementia
Evolution of Pain Assessments in Dementia For personal use only PainChek™ 2003 2017 • 2002 2004 AGS 10
Slide 11: The PainChek Solution
The PainChek® solution For personal use only • A secure, validated, medical device in the form of a mobile app • Uses existing smartphone and tablet hardware1 • Artificial Intelligence (AI) technology to analyze facial expressions indicative of pain in real time 1 Edge devices (smartphones and table
Slide 12: Helping carers identify the presence of pain
Helping carers identify the For personal use only presence of pain when it isn’t obvious… 12
Slide 13: Quantifying the severity of pain
Helping carers identify the For personal use only presence of pain when it isn’t obvious… ...quantifying the severity of pain when it is…… 13
Slide 14: Monitoring the effectiveness of interventions
Helping carers identify the For personal use only presence of pain when it isn’t obvious… ...quantifying the severity of pain when it is…… and monitoring the effectiveness of interventions 14
Slide 15: PainChek Case Study
PainChek® Case Study 1 Case Study 2 ▪ 84 year old male ▪ 72 year old female For personal use only ▪ Referred with physical ▪ Referred with agitated aggression during care behaviour, restless at night ▪ Pain suspected to be impacting on behaviour ▪ Pain suspected to be impacting on behaviour ▪ PainCh
Slide 16: PainChek Benefits Impacts All Key Stakeholders
PAINCHEK® BENEFITS IMPACTS ALL KEY STAKEHOLDERS For personal use only • Improve quality of life Clinical • Reduce rates and severity of behavioural and psychological symptoms Utility • Reduce rates of incorrectly prescribed antipsychotics • Point of Care testing • Automated documentation Cost Benefi
Slide 17: Innate Human Behaviours Are Expressed Through Facial Muscles
INNATE HUMAN BEHAVIOURS ARE EXPRESSED THROUGH FACIAL MUSCLES For personal use only BRAIN REACTION FACIAL MOVEMENTS FACIAL TRACKING ▪ 20 – 40 ms ▪ 43 facial muscles ▪ 68 or 170 points 17
Slide 18: The PainChek Dementia App
The PainChek® Dementia App For personal use only ▪ Automated facial pain analysis: • 3 second video of patient face • recognises 9 micro-facial expressions that indicate pain ▪ Digital questionnaire checklist: • guide the carer in other pain assessment factors e.g. movement, vocalization • leading q
Slide 19: Dementia App market entry strategy - Australia
PainChek® Dementia App market entry strategy - Australia Residential For personal use only Aged Care (RAC)* 210,000 beds HCP - Enterprise Home Carers Channel Operators 3rd Party (HCO) Software 200,000 Suppliers Packages Home Care 330,000 people living Home Carer Channel with dementia at home 19
Slide 20: PainChek gaining strong market momentum
PainChek® gaining strong market momentum For personal use only Residential Aged Care Clients Contracted Number of Residential Aged Clinical PainChek Assessments (Under Contract) Care Beds (Cumulative for 2018. Total since inception > 6,900) 25 (based on contracts signed as of month end) 6000 4,776 2
Slide 21: Our Clients; Our Partners & Supporters
Our Clients * For personal use only Our Partners & Supporters *Nationwide
Slide 22: PainChek portfolio transcends the Dementia Journey
PainChek® portfolio transcends the Dementia Journey For personal use only HCP Carers HCO Physio GP Physio GP/Spec GP Care Environment Home Home RAC Consumer / Carer Family Family + HCO RAC staff Dementia Stage Onset Dementia Moderate Dementia Moderate to Severe Dementia PainChek® Version Consumer Sh
Slide 23: Dementia Training Australia: PainChek online Carer training videos
Dementia Training Australia : PainChek® on line Carer training videos For personal use only 23
Slide 24: PainChek Shared Care capability
PainChek® Shared Care capability - facilitates integrated pain management For personal use only Residential Home Care Home Carer Aged Care Operator’s • Majority of people living with Dementia live at home (approx. 300,000 in Australia) • Consumer Directive Care (CDC) initiative: Governments globally
Slide 25: PainChek global market entry strategy
PainChek® global market entry strategy: current regulatory clearance provides access for up to 40% of the global market For personal use only 1 2 3 Australia International US entry 2019/20 2017/18 Expansion 2018/19 Goal: Established sales, business model and Goal: Expand into international markets u
Slide 26: PainChek Patent Status
PainChekTM Patent Status For personal use only • Patent clearance for PCT filing received in August 2016 • National filings commenced Feb 2017 in all key global markets; – Europe – US – Australia – China – Japan 26
Slide 27: PainChek Key Milestones Summary
PainChek® Key Milestones Summary Dementia App Pre-Verbal Children Apps For personal use only Q4 2017 Q4 2017 First commercial sales achieved in Q3 & Q4 2017 Completion of children video library, data model and algorithm – on track Q1 2018 Built Australian commercial team to execute on sales Q1-2 201
Slide 28: PainChek Ltd Board
PainChek Ltd Board For personal use only • John Murray, Chair – 25 years in tech VC, multiple board roles including aged care • Philip Daffas, MD – Senior global healthcare executive : Global market experience with Roche Diagnostics and Cochlear • Ross Harricks, NED – Senior global medical device ex
Slide 29: Financial Update
Financial Update For personal use only • Current shares on issue: 837,884,587 • Market cap undiluted at 5c = $42m • Market Cap fully diluted at 5c = $51m • Unlisted Options on issue: 174,917,730 • Fully diluted capital:1,012,802,317 • Cash at bank: 30 Sept 2018: $2.6m 29
Slide 30: PainChek Highlights
PainChek® Highlights Large initial global market For personal use only opportunities 47M people living with dementia Proven business model worldwide - CAGR 3% Accelerating sales in Residential Aged 400M children aged between 0-3 years Care (RAC) including Allity, Top 5 RAC old Partnering with 3rd Pa
Slide 31: PainChek Ltd
For personal use only Company Presentation October 2018 PainChek Ltd 31